Cancer 52 patient survey

Cancer 52, an alliance of over 90 organisations, united in improving the future for everyone affected by rare and less common cancers, has published the results of its patient survey in which many mesothelioma patients took part.

This patient survey looked at the impact of the Covid-19 pandemic on people with rare and less common cancers ran from early December 2020 to mid-January 2021. Over 500 people from across England responded. Some of the key findings included:
• People diagnosed since the pandemic faced delays – either because they were concerned about contacting their GP or test and scans had been delayed
• One in ten people who had received treatment since the pandemic began had not had the type of treatment they were expecting to receive
• One in ten people had not been able to access their GP during the pandemic. 20% had been able to see their GP in person and 70% had been able to have a virtual or telephone appointment

The results can be seen at and are also being shared with NHS England, and other key stakeholders in the charity sector and industry.

Look out for Patient and Carer Day 2022

Each year, Mesothelioma UK holds its annual patient and carer day - a day of learning, shared experiences and a chance to come together. The event hosts a number of key speakers discussing, surgery, new treatment and trials and many other concerns or questions that...

Access to immunotherapy update

As you may be aware from previous issues of our magazine, first line immunotherapy (nivolumab and ipilimumab) for the treatment of mesothelioma is currently under consideration by the National Institute for Health and Care Excellence (NICE) following the results of...

Mesothelioma UK partners with Healthinote

Mesothelioma UK has joined Healthinote, an online digital platform allowing doctors, nurses and pharmacists to find and share reliable health information with their patients. Used by over 3,000 GP practices in the UK, Heathinote enables people to be given an...